Aug. 6 at 12:52 AM
$IOVA I hope that i'm wrong, but I don't see us receiving positive news with ER. Mgmt needs to temporarily increase the treatment price from
$560K to whatever the price should be until we are breakeven. Once we are breakeven then lower the treatment price. It does not help anyone if we go out of business like
$BLUE. We need to be more like
$ABEO, they recently received their FDA approval, they charge
$3.1M per one-time treatment and will be profitable by 1qt 2026. At the current rate
$IOVA will need to dilute again lowering our share price again and eventually either go bankrupt or be sold for pennies on the $. Again, I hope I'm wrong but the foggy path seems to not be on a healthy path "UNLESS" mgmt changes. All the best to everyone that supports Iovance. GLTA!!!
